The MARGOT/TBCRC052 trial, presented at SABCS 2024, explored the efficacy of margetuximab + paclitaxel + pertuzumab (TMP) versus the standard trastuzumab + paclitaxel + pertuzumab (THP) in HER2+ stage II-III breast cancer patients.
Key Findings:
No statistically significant difference in pathologic complete response (pCR) rates between TMP and THP.
TMP showed a numerical improvement in pCR rate (56% vs. 46%) but did not reach statistical significance (p=0.25).
Safety and tolerability were comparable between regimens, though TMP had higher infusion-related reaction rates.
Further analysis will investigate immune biomarkers to refine treatment strategies.
These findings reinforce the complexity of treatment decision-making in early-stage HER2+ breast cancer and the importance of personalized therapeutic approaches.
For more details, check out the full study:https://lnkd.in/gVihTcUT
A huge thank you to all the researchers, clinicians, and patients who contributed to this critical work
